Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-29

Gossamer Bio (GOSS)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,300,455
Faheem Hasnain total, FY2025
30th
CEO pay percentile vs peers
CEO-to-median pay ratio
93.65%
Say-on-pay support, latest vote
Companies that benchmark against GOSS
9 companies name GOSS as a compensation peer

Each company listed discloses GOSS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GOSS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Faheem Hasnain$649,649$0$0$1,392,006$254,800$0$4,000$2,300,455
Chairman, President and Chief Executive Officer
Bryan Giraudo519,83000576,688152,91304,0001,253,431
Chief Operating Officer and Chief Financial Officer
Robert Smith463,50075,0000517,031121,21304,0001,180,744
Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Faheem Hasnain$2,300,455$2,005,432+295,023
Bryan Giraudo1,253,4311,171,904+81,527
Robert Smith1,180,744

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
John D. QuiselDirector2026-06-04A115,000$0$0Derivative, Class A CommonForm 4 ↗
Skye DrynanDirector2026-06-04A115,00000Derivative, Class A CommonForm 4 ↗
Thomas O. DanielDirector2026-06-04A115,00000Derivative, Class A CommonForm 4 ↗
Steven D. NathanDirector2026-06-04A115,00000Derivative, Class A CommonForm 4 ↗
Russell CoxDirector2026-06-04A115,00000Derivative, Class A CommonForm 4 ↗
Sandra MilliganDirector2026-06-04A115,00000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Robert SmithOPTION$517,031
Bryan GiraudoOPTION576,688
Faheem HasnainOPTION1,392,006
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Robert Smith$0$0$517,0310.0%
Bryan Giraudo00576,6880.0%
Faheem Hasnain001,392,0060.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Bryan GiraudoOption638,0001.13
Robert SmithPSU162,500503,750
Faheem HasnainOption683,5940.97
Bryan GiraudoOption66,0941.21
Faheem HasnainOption1,540,0001.13
Faheem HasnainOption209,6360.84
Faheem HasnainOption170,1571.21
Bryan GiraudoOption283,2040.97
Faheem HasnainPSU437,5001,356,250
Robert SmithOption750,0000.97
Bryan GiraudoPSU181,250561,875
Faheem HasnainOption750,0001.36
Bryan GiraudoOption86,8500.84
Robert SmithOption572,0001.13
Robert SmithOption487,5000.97
05

Incentive-plan design — the Compensation Discussion & Analysis

The key objectives of our executive compensation program are: To attract, engage and retain an executive team who will provide leadership for our future success by providing competitive total pay opportunities. To establish a direct link between our business results, individual executive performance and total executive compensation. To align the interests of our named executive officers with those of our stockholders.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantAlpine Rewards
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-04111,286,5507,545,502137,46193.65%Passed
20252025-06-25125,358,4853,769,651472,93097.08%Passed
20242024-06-06115,985,18240,356,9195,831,13374.19%Passed
20232023-06-0838,901,35519,975,93187,31666.07%Passed
20222022-06-0946,093,471345,87631,93099.26%Passed
20212021-06-0950,886,375298,5412,688,85799.42%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0493.65%a
20252025-06-2597.08%b
20242024-06-0674.19%c

a. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.

b. Approved under the standard stated in the filing — “Abstentions are not an affirmative or negative vote on a proposal, so abstaining does not count as a vote cast and has no effect for purposes of determining whether our stockholders have ratified the appointment of Ernst & Young LLP, our independent registered public accounting firm, whether our stockholders have approved the compensation of the named executive officers, or whether our stockholders have approved the amendment and restatement our 2019 Incentive Award Plan.”.

c. Approved under the standard stated in the filing — “Abstentions are not an affirmative or negative vote on a proposal, so abstaining does not count as a vote cast and has no effect for purposes of determining whether our stockholders have ratified the appointment of Ernst & Young LLP, our independent registered public accounting firm, or whether our stockholders have approved the compensation of the named executive officers.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Thomas Daniel, M.DIndependent · Lead Independent Director · Compensation · Nominating/Governance$76,875$0$122,694$0$199,569
Russell CoxIndependent · Audit · Compensation (Chair)63,6250122,6940186,319
Skye DrynanIndependent · Audit (Chair)58,7500122,6940181,444
Sandra Milligan, M.D., J.DIndependent · Compensation · Nominating/Governance (Chair)56,6250122,6940179,319
John Quisel, Ph.D., J.DIndependent · Audit49,3750122,6940172,069
Steven Nathan, M.DIndependent · Nominating/Governance44,7500122,6940167,444
Faheem HasnainEmployee director · Board Chair00000
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)15,000 / 12,000 / 8,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$350,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$350,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Gossamer Bio names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Gossamer Bio.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1RAPT Therapeutics2024Brian Wong$630,000$0$5,927,297$416,000$6,979,539
2Allakos2023Robert Alexander805,4602,171,3402,623,519684,6416,299,426
3Allogene Therapeutics2025David Chang724,0002,409,5372,588,329400,0106,136,093
4AnaptysBio2025Daniel Faga706,0111,592,0013,345,653465,9686,133,943
5Erasca2025Jonathan Lim670,40003,135,250482,6884,298,838
6Poseida Therapeutics2023Mark Gergen611,6671,442,2851,413,936336,4203,818,018
7aTyr Pharma2025Sanjay Shukla638,97702,595,200210,8623,456,253
8Atea Pharmaceuticals2025Jean-Pierre Sommadossi703,4901,315,800962,368422,0943,403,752
9Kodiak Sciences2025Victor Perlroth792,4970923,032772,8242,499,221
10Gossamer Bio2025Faheem Hasnain649,64901,392,006254,8002,300,455
11Alector2025Arnon Rosenthal678,100422,876558,216325,4881,995,018
12Mersana Therapeutics2024Michael Huber632,500133,635518,044322,5751,613,754
13Zentalis Pharmaceuticals2025Julie Eastland700,00099,77256,975441,0001,300,731
Fulcrum Therapeuticsnot in coverage universe
Mineralys Therapeuticsnot in coverage universe
Ventyx Biosciencesnot in coverage universe
Annexonnot in coverage universe
Trevi Therapeuticsnot in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Gossamer Bio65%not disclosedNoAlpine Rewards
Alector80%not disclosednot disclosedPearl Meyer & Partners, LLC
Allakosnot disclosedOptions 55 · RSU 45NoCompensia
Allogene Therapeutics85%Options 55 · RSU 25 · PSU 20NoCompensia
AnaptysBio110%not disclosedNoAlpine Rewards
Annexonnot disclosednot disclosednot disclosednot disclosed
Atea Pharmaceuticalsnot disclosednot disclosedNoAon (Aon plc, Human Capital Solutions Practice)
aTyr Pharma60% (Committee lowered payout from 75% achievement to 60% given EFZO-FIT study results)%Options 100not disclosedRadford (Aon plc Rewards Solutions)
Erasca120%Options 100not disclosedAlpine Rewards, LLC
Fulcrum Therapeuticsnot disclosednot disclosednot disclosednot disclosed
Kodiak Sciences150%Options 100not disclosedCompensia, Inc.
Mersana Therapeutics85%Options 75 · RSU 25not disclosedPearl Meyer & Partners, LLC
Mineralys Therapeuticsnot disclosednot disclosednot disclosednot disclosed
Poseida Therapeuticsnot disclosednot disclosednot disclosedAon
RAPT Therapeutics120%Options 100not disclosedAon plc/Radford
Trevi Therapeuticsnot disclosednot disclosednot disclosednot disclosed
Ventyx Biosciencesnot disclosednot disclosednot disclosednot disclosed
Zentalis Pharmaceuticals105%not disclosednot disclosedAnderson Pay Advisors LLC / Pay Governance LLC

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Faheem HasnainDEF 14A2026-04-240001728117-26-000027Section “Summary Compensation Table”. As printed: 2,300,455. Filing ↗machine: r2 · c48 · span 378559–378568
2Section 01, Bryan GiraudoDEF 14A2026-04-240001728117-26-000027Section “Summary Compensation Table”. As printed: 1,253,431. Filing ↗machine: r5 · c48 · span 385546–385555
3Section 01, Robert SmithDEF 14A2026-04-240001728117-26-000027Section “Summary Compensation Table”. As printed: 1,180,744. Filing ↗machine: span 392612–392621
4Section 03, Robert Smith OPTIONDEF 14A2026-04-240001728117-26-000027Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r8 · c13 · span 391387–391394
5Section 03, Bryan Giraudo OPTIONDEF 14A2026-04-240001728117-26-000027Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r5 · c13 · span 384546–384553
6Section 03, Faheem Hasnain OPTIONDEF 14A2026-04-240001728117-26-000027Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r2 · c13 · span 377176–377185
7Section 07, pay ratio10-K2026-03-170001728117-26-000017Section “CEO Pay Ratio”. As printed: —. Filing ↗
8Section 08, Thomas Daniel, M.DDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 199,569. Filing ↗machine: t11 · r5 · c11 · span 196133–196140
9Section 08, Russell CoxDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 186,319. Filing ↗machine: t11 · r4 · c11 · span 194242–194249
10Section 08, Skye DrynanDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 181,444. Filing ↗machine: t11 · r3 · c11 · span 192384–192391
11Section 08, Sandra Milligan, M.D., J.DDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 179,319. Filing ↗machine: t11 · r6 · c10 · span 197646–197653
12Section 08, John Quisel, Ph.D., J.DDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 172,069. Filing ↗machine: t11 · r7 · c10 · span 199406–199413
13Section 08, Steven Nathan, M.DDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 167,444. Filing ↗machine: t11 · r2 · c11 · span 190775–190782
14Section 08, Faheem HasnainDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 0. Filing ↗
15Section 02, John D. Quisel 2026-06-04Form 42026-06-050001728117-26-000047Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Skye Drynan 2026-06-04Form 42026-06-050002015102-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Thomas O. Daniel 2026-06-04Form 42026-06-050001538894-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Steven D. Nathan 2026-06-04Form 42026-06-050002015114-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Russell Cox 2026-06-04Form 42026-06-050001512984-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Sandra Milligan 2026-06-04Form 42026-06-050001859810-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
21Section 06, 2026 voteForm 8-K2026-06-050001728117-26-000042Item 5.07 · say-on-pay result. As reported: 93.65% (votes for as printed: 111,286,550). Filing ↗
22Section 06, 2025 voteForm 8-K2025-06-250001728117-25-000043Item 5.07 · say-on-pay result. As reported: 97.08% (votes for as printed: 125,358,485). Filing ↗
23Section 06, 2024 voteForm 8-K2024-06-100001728117-24-000069Item 5.07 · say-on-pay result. As reported: 74.19% (votes for as printed: 115,985,182). Filing ↗
24Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
25Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
26Section 09b board cost (computed)ComputedcomputedCash 350,000 + equity 0 + all other 0 = 350,000, summed across the director compensation table rows.machine: formula: Σ = 350,000
27RAPT Therapeutics, Section 10b CEO totalDEF 14A2025-04-140000950170-25-053517CEO total compensation as printed in RAPT Therapeutics's own proxy. As printed: 6,979,539. Filing ↗machine: r2 · c23 · span 816852–816861
28Allakos, Section 10b CEO totalDEF 14A2024-04-230000950170-24-047043CEO total compensation as printed in Allakos's own proxy. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107
29Allogene Therapeutics, Section 10b CEO totalDEF 14A2026-04-300001628280-26-028948CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023
30AnaptysBio, Section 10b CEO totalDEF 14A2026-06-290001193125-26-288408CEO total compensation as printed in AnaptysBio's own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415
31Erasca, Section 10b CEO totalDEF 14A2026-04-280001193125-26-187361CEO total compensation as printed in Erasca's own proxy. As printed: 4,298,838. Filing ↗machine: r2 · c31 · span 221524–221533
32Poseida Therapeutics, Section 10b CEO totalDEF 14A2024-04-250000950170-24-048291CEO total compensation as printed in Poseida Therapeutics's own proxy. As printed: 3,818,018. Filing ↗machine: span 428155–428164
33aTyr Pharma, Section 10b CEO totalDEF 14A2026-03-260001339970-26-000021CEO total compensation as printed in aTyr Pharma's own proxy. As printed: 3,456,253. Filing ↗machine: t11 · r2 · c21 · span 533754–533763
34Atea Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-270001193125-26-182293CEO total compensation as printed in Atea Pharmaceuticals's own proxy. As printed: 3,403,752. Filing ↗machine: r3 · c22 · span 1526943–1526952
35Kodiak Sciences, Section 10b CEO totalDEF 14A2026-04-220001193125-26-170429CEO total compensation as printed in Kodiak Sciences's own proxy. As printed: 2,499,221. Filing ↗machine: r4 · c14 · span 905058–905068
36Gossamer Bio (subject), Section 10b CEO totalDEF 14A2026-04-240001728117-26-000027CEO total compensation as printed in Gossamer Bio's own proxy. As printed: 2,300,455. Filing ↗machine: r2 · c48 · span 378559–378568
37Alector, Section 10b CEO totalDEF 14A2026-04-280001193125-26-186928CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674
38Mersana Therapeutics, Section 10b CEO totalDEF 14A2025-04-290001104659-25-040448CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. Filing ↗machine: t16 · r1 · c41 · span 608188–608197
39Zentalis Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-300001725160-26-000027CEO total compensation as printed in Zentalis Pharmaceuticals's own proxy. As printed: 1,300,731. Filing ↗machine: r2 · c48 · span 319348–319357
40Section 10a, Allogene Therapeutics reciprocityDEF 14A0001628280-26-028948Allogene Therapeutics's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
41Section 10a, Alector reciprocityDEF 14A0001193125-26-186928Alector's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
42Section 10a, aTyr Pharma reciprocityDEF 14A0001339970-26-000021aTyr Pharma names Gossamer Bio in its own disclosed peer group (read from its most recent proxy). Filing ↗
43Section 10a, Kodiak Sciences reciprocityDEF 14A0001193125-26-170429Kodiak Sciences's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
44Section 10a, Mersana Therapeutics reciprocityDEF 14A0001104659-25-040448Mersana Therapeutics's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
45Section 10a, Allakos reciprocityDEF 14A0000950170-24-047043Allakos's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
46Section 10a, AnaptysBio reciprocityDEF 14A0001193125-26-288408AnaptysBio's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
47Section 10a, Atea Pharmaceuticals reciprocityDEF 14A0001193125-26-182293Atea Pharmaceuticals names Gossamer Bio in its own disclosed peer group (read from its most recent proxy). Filing ↗